Abstract Number: 0764 • ACR Convergence 2025
Frequency of large vessel vasculitis in giant cell arteritis with and without adventiitis of temporal artery – Is the presence of temporal arteritis sufficient to diagnose giant cell arteritis?-
Background/Purpose: Takayasu arteritis (TAK) and giant cell arteritis (GCA) belong to the large vessel vasculitis group. Differences between the two diseases have been reported based…Abstract Number: 0747 • ACR Convergence 2025
Patterns of Macrophage Polarization Induced by Serum from Patients with Giant Cell Arteritis and Takayasu’s Arteritis
Background/Purpose: Macrophages play a central role in the pathogenesis of large-vessel vasculitides, including giant cell arteritis (GCA) and Takayasu’s arteritis (TAK). Characterizing patterns of macrophage…Abstract Number: 1619 • ACR Convergence 2025
Systemic Immune-Inflammation Index Is Superior to Neutrophil-to-Lymphocyte Ratio for Assessing Disease Activity in Polymyalgia Rheumatica and Giant Cell Arteritis
Background/Purpose: Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are chronic inflammatory disorders predominantly affecting patients over 50. Despite unclear etiopathogenesis, both conditions share central…Abstract Number: 0762 • ACR Convergence 2025
Relapse rate, predictors of relapses and impact of introduction of interleukin-6-receptor inhibition on relapse rate in GCA- Data from the large REATS cohort from six vasculitis centers
Background/Purpose: The diagnosis and management of giant cell arteritis (GCA) has significantly evolved over the last decades, mainly due to advances in imaging techniques and…Abstract Number: 0746 • ACR Convergence 2025
Impact of Frailty on Mortality in GCA and PMR: A Retrospective Cohort
Background/Purpose: Frailty, a syndrome associated with decreased physiologic reserve, is associated with adverse outcomes. The prevalence and impact of baseline frailty on the risk of…Abstract Number: 1617 • ACR Convergence 2025
Evaluating Familiarity and Knowledge Gaps in Polymyalgia Rheumatica Among Public Health Professionals
Background/Purpose: Polymyalgia rheumatica (PMR) is a commonly occurring inflammatory condition affecting older adults, primarily presenting with bilateral shoulder and hip stiffness. Despite its high prevalence…Abstract Number: 0763 • ACR Convergence 2025
Diagnostic Utility of Temporal Artery Biopsy in Giant Cell Arteritis: A Single Center Experience
Background/Purpose: Giant cell arteritis (GCA) is predominantly large vessel vasculitis that has a specific prediliction for vasculature of the head, eyes and jaw and if…Abstract Number: 0745 • ACR Convergence 2025
Prevalence and Clinical Significance of Low ESR and CRP in Giant Cell Arteritis: A Population Based Study
Background/Purpose: Traditionally, elevated erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) had been considered a hallmark of GCA and both are included in the 2022…Abstract Number: 1616 • ACR Convergence 2025
Short-Course Prednisone and Methotrexate in Polymyalgia Rheumatica: A Potential Therapeutic Approach
Background/Purpose: Despite being considered an easy-to-diagnose and easy-to-treat condition, the optimal treatment of PMR is far from being fully elucidated. Three recently published trials have…Abstract Number: 0761 • ACR Convergence 2025
Fast-Track Clinics Improve Visual Outcomes in Giant Cell Arteritis: A Meta-Analysis
Background/Purpose: Giant Cell Arteritis (GCA) is a chronic, inflammatory condition, primary affecting the medium and larger arteries, usually in patients older than 50 years. It…Abstract Number: 0744 • ACR Convergence 2025
Age and Sex Influence on Clinical Manifestations of Giant Cell Arteritis: Results from the ARTESER Registry
Background/Purpose: Giant cell arteritis (GCA) is a large vessel vasculitis that predominantly affects older adults, with a higher prevalence in women. Previous studies exploring sex-related…Abstract Number: 2704 • ACR Convergence 2025
Complete metabolic response on PET/CT in giant-cell arteritis-related large vessel vasculitis : comparison of two strategies using glucocorticoids or glucocorticoids + tocilizumab
Background/Purpose: Persistent large-vessel vasculitis (LVV) on PET/CT in giant-cell arteritis (GCA) is associated with a higher risk of aortic dilation. Few data are available on…Abstract Number: 1614 • ACR Convergence 2025
A Systematic Literature Review to Inform the EULAR Recommendations for the Management of Polymyalgia Rheumatica and Large Vessel Vasculitis: Focus on Referral and Diagnosis
Background/Purpose: European Alliance of Associations for Rheumatology (EULAR) recommendations for the management of Polymyalgia Rheumatica (PMR) and Large Vessel Vasculitis (LVV) date back to 2015…Abstract Number: 0760 • ACR Convergence 2025
The Efficacy Of Targeted Therapies In Giant Cell Arteritis: A Systematic Review and Meta-Analysis
Background/Purpose: To assess the sustained remission rates of the targeted therapies in 52th week in patients with giant cell arteritis (GCA).Methods: We performed a systematic…Abstract Number: 0743 • ACR Convergence 2025
Giant Cell Arteritis Relapse After Treatment with Two Months of Prednisone and 12 Months of Tocilizumab
Background/Purpose: The optimal duration of tocilizumab (TCZ) treatment for giant cell arteritis (GCA) is unclear. Observational studies have shown that 50-60% of patients relapse after…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 36
- Next Page »
